$XTLB

XTL BIOPHARMACEUTICALS LTD

XTL Biopharmaceuticals is a biopharmaceutical company based in Ramat Gan, Israel. It acquires and develops drugs for autoimmune diseases. Its main drug candidate, hCDR1, targets systemic lupus erythematosus and Sjogren's syndrome. The company licenses hCDR1 from Yeda for research, development and commercialization across various indications.

0
0
1

No SEC Form 4 filings for $XTLB in the last 30 days.

See all $XTLB insider activity →
Med

XTL BIOPHARMACEUTICALS LTD (XTLB): Financial results for H1 2026

XTL BIOPHARMACEUTICALS LTD (XTLB) furnished an SEC Form 6-K — earnings release. RAMAT GAN, ISRAEL - (November 18, 2026) – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”) today announced financial results for the six months ended June 30, 2026. On June 30, 2026, the Company completed the acquisition of 83.4% of the share cap

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio from 1 ADS to 100 ordinary shares, to 1 ADS to 400 ordinary shares, effective March 25, 2026. This change is equivalent to a one-for-four reverse ADS split, meaning existing ADS holders will exchange four ADSs for one new ADS. The company expects a proportional increase in its ADS trading price and states the change will not affect its underlying ordinary shares.

XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance

XTL Biopharmaceuticals (XTLB) received a Nasdaq notification on December 22, 2025, for failing to meet the minimum $1 bid price requirement for 30 consecutive business days. The company has until June 22, 2026, to regain compliance and is exploring options, including a potential reverse stock split, to avoid delisting. This situation highlights the ongoing market pressure on XTLB and creates uncertainty for shareholders regarding its access to U.S. capital markets.

XTLB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning XTLB (XTL BIOPHARMACEUTICALS LTD). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent XTLB coverage spans financial news and earnings.

What's driving XTLB

  • Earnings show no revenue and a net loss, while dilution from the acquisition and new warrants may pressure the share price.

    SEC EDGAR 6-K · Nov 18, 2026

  • The ADS ratio change represents a reverse split, which typically results in an increase in the trading price per ADS without affecting the underlying equity value. This adjustment may influence short-term trading behavior but is unlikely to alter long-term fundamentals.

    The Manila Times · Mar 21, 2026

  • XTL Biopharmaceuticals faces a Nasdaq bid-price deficiency, with a deadline of June 2026 to regain compliance. The company's exploration of a reverse stock split indicates efforts to avoid delisting. This situation introduces short-term volatility risk but may also present a potential rebound opportunity if the company successfully regains compliance.

    TipRanks · Dec 30, 2025

AlphAI scores every news story that mentions XTLB with an AI model for sentiment and relevance, and aggregates insider trades from XTL BIOPHARMACEUTICALS LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XTLB

Score
$XTLBMedEarnings

XTL BIOPHARMACEUTICALS LTD (XTLB): Financial results for H1 2026

XTL BIOPHARMACEUTICALS LTD (XTLB) furnished an SEC Form 6-K — earnings release. RAMAT GAN, ISRAEL - (November 18, 2026) – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”) today announced financial results for the six months ended June 30, 2026. On June 30, 2026, the Company completed the acquisition of 83.4% of the share cap

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio from 1 ADS to 100 ordinary shares, to 1 ADS to 400 ordinary shares, effective March 25, 2026. This change is equivalent to a one-for-four reverse ADS split, meaning existing ADS holders will exchange four ADSs for one new ADS. The company expects a proportional increase in its ADS trading price and states the change will not affect its underlying ordinary shares.

XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance

XTL Biopharmaceuticals (XTLB) received a Nasdaq notification on December 22, 2025, for failing to meet the minimum $1 bid price requirement for 30 consecutive business days. The company has until June 22, 2026, to regain compliance and is exploring options, including a potential reverse stock split, to avoid delisting. This situation highlights the ongoing market pressure on XTLB and creates uncertainty for shareholders regarding its access to U.S. capital markets.

Related tickers